Dr Rackham is a world expert in developing computational approaches for cell reprogramming and disease-gene association. His group works on identifying key regulators that can control cell fate to find novel routes for cell conversion or targeted therapies. He has extensive expertise in high-throughput sequencing data, biological network analysis and statistics. He completed his PhD in complexity sciences in 2012, after which he became an MRC career development fellow at Imperial College London. In 2015 he moved to Duke-NUS medical school as a senior research fellow and subsequently started his group in 2016, focusing on data-driven tools for cell reprogramming and disease. He became jointly appointed at Southampton University in 2020 as an Associate Professor in Systems Biology. He is also the theme lead for Cell and Molecular Medicine at the Alan Turing Institute.
His work has been the focus of patent applications and licensing deals. He has co-founded a spin-out company Mogrify Ltd. (mogrify.co.uk), developing cell therapy products for various clinical applications.
In the past hypothesis-driven research in the life sciences has been the domain of experimental biologists, with the role of biostatisticians and bioinformaticians being one of support. This is no longer the case. As the “data deluge” continues, my research interests have focused on using biological “big data” to create and test hypotheses.
My primary research interest is understanding how genes and drugs can coordinate changes in cellular phenotypes and use this to treat disease or initiate transdifferentiation. I have approached this problem by integrating varied data sources, developing algorithms and close collaboration with experimental scientists.